Published in Haematologica on June 11, 2012
Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. Oncotarget (2015) 0.80
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs (2015) 0.75
Exploring site-specific N-glycosylation of HEK293 and plant-produced human IgA isotypes. J Proteome Res (2017) 0.75
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy. Bioengineering (Basel) (2017) 0.75
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther (1999) 8.28
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood (1997) 3.19
Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol (2000) 3.19
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 2.69
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 2.62
The function of immunoglobulin A in immunity. J Pathol (2006) 2.31
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
Transepithelial transport of immunoglobulins. Annu Rev Immunol (1994) 2.10
IgA Fc receptors. Annu Rev Immunol (2001) 1.98
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2002) 1.87
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother (2000) 1.60
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol (2002) 1.52
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol (2009) 1.49
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes. J Exp Med (1982) 1.39
Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol (1987) 1.38
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol (2009) 1.29
Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol (1996) 1.15
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood (2002) 1.12
A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol (2011) 1.07
Human IgA1 initiates complement-mediated killing of Neisseria meningitidis. J Immunol (1989) 1.04
Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood (1999) 1.03
Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol (2005) 1.01
Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol (2010) 0.97
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol (2007) 0.96
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood (1997) 0.93
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood (2002) 0.92
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol (2011) 0.90
Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res (1999) 0.89
Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. Blood (2009) 0.89
Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of fcalpha receptors (FcalphaR) with a monoclonal antibody, MIP8a. Clin Exp Immunol (2000) 0.86
Fc alpha receptors mediate release of tumour necrosis factor-alpha and interleukin-6 by human monocytes following receptor aggregation. Immunology (1995) 0.85
Monomeric and polymeric IgA show a similar association with the myeloid FcalphaRI/CD89. Mol Immunol (2006) 0.84
Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. J Immunol Methods (2008) 0.82
Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies. Arch Immunol Ther Exp (Warsz) (2010) 0.78
Interaction of immunoglobulin A with complement and phagocytic cells. Prog Clin Biol Res (1989) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther (2010) 2.15
Macrophages in skin injury and repair. Immunobiology (2011) 2.00
Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol (2003) 1.76
A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells. Blood (2014) 1.68
The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog (2007) 1.61
Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood (2006) 1.58
Flexible long-range loops in the VH gene region of the Igh locus facilitate the generation of a diverse antibody repertoire. Immunity (2013) 1.56
The IgH locus 3' regulatory region: pulling the strings from behind. Adv Immunol (2011) 1.55
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene (2002) 1.53
The IgH 3' regulatory region controls somatic hypermutation in germinal center B cells. J Exp Med (2013) 1.53
Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J Hepatol (2010) 1.52
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 1.52
Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice. J Immunol (2005) 1.50
Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol (2011) 1.42
The beta-globin HS4 insulator confers copy-number dependent expression of IgH regulatory elements in stable B cell transfectants. Immunol Lett (2003) 1.41
Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol (2005) 1.40
The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype. J Immunol (2007) 1.37
Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. Nature (2009) 1.34
Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. Cytotherapy (2013) 1.27
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol (2009) 1.24
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
Mantle cell lymphoma-like lymphomas in c-myc-3'RR/p53+/- mice and c-myc-3'RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin. Oncotarget (2012) 1.17
Mannan chain length controls lipoglycans signaling via and binding to TLR2. J Immunol (2008) 1.17
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell (2012) 1.16
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs (2015) 1.16
The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg (2009) 1.15
CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol (2008) 1.15
Ig synthesis and class switching do not require the presence of the hs4 enhancer in the 3' IgH regulatory region. J Immunol (2009) 1.15
Immunoglobulin class-switch recombination in mice devoid of any S mu tandem repeat. Blood (2004) 1.14
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
The immunoglobulin heavy-chain locus hs3b and hs4 3' enhancers are dispensable for VDJ assembly and somatic hypermutation. Blood (2003) 1.10
Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res (2002) 1.10
Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med (2011) 1.09
Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation. Proc Natl Acad Sci U S A (2010) 1.09
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol (2008) 1.08
Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med (2012) 1.08
A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol (2011) 1.07
Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood (2012) 1.06
Interallelic class switch recombination contributes significantly to class switching in mouse B cells. J Immunol (2005) 1.05
The IgH 3' regulatory region and its implication in lymphomagenesis. Eur J Immunol (2010) 1.05
Enhancers located in heavy chain regulatory region (hs3a, hs1,2, hs3b, and hs4) are dispensable for diversity of VDJ recombination. J Biol Chem (2012) 1.04
Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am J Kidney Dis (2005) 1.03
Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther (2013) 1.03
B cell development arrest upon insertion of a neo gene between JH and Emu: promoter competition results in transcriptional silencing of germline JH and complete VDJ rearrangements. J Immunol (2002) 1.03
Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol (2003) 1.03
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis (2010) 1.02
Insulators to improve expression of a 3(')IgH LCR-driven reporter gene in transgenic mouse models. Biochem Biophys Res Commun (2003) 1.02
AID-induced remodeling of immunoglobulin genes and B cell fate. Oncotarget (2014) 1.02
Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol (2005) 1.01
Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome. Nephrol Dial Transplant (2010) 1.01
Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib Nephrol (2011) 0.99
Elucidation of the enigmatic IgD class-switch recombination via germline deletion of the IgH 3' regulatory region. J Exp Med (2014) 0.99
A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice. Am J Pathol (2012) 0.99
In vivo redundant function of the 3' IgH regulatory element HS3b in the mouse. J Immunol (2010) 0.99
Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res (2009) 0.99
Detrimental dermal wound healing: what can we learn from the oral mucosa? Wound Repair Regen (2013) 0.99
Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol (2003) 0.97
AID-driven deletion causes immunoglobulin heavy chain locus suicide recombination in B cells. Science (2012) 0.96
Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett (2008) 0.95
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol (2007) 0.95
IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling. J Immunol (2012) 0.95
Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells. PLoS Biol (2013) 0.95
Multiple RNA surveillance mechanisms cooperate to reduce the amount of nonfunctional Ig kappa transcripts. J Immunol (2010) 0.95
RNA surveillance down-regulates expression of nonfunctional kappa alleles and detects premature termination within the last kappa exon. Proc Natl Acad Sci U S A (2004) 0.94
The Fc receptor for IgA (FcalphaRI, CD89). Immunol Lett (2004) 0.93
Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias. J Leukoc Biol (2004) 0.92
A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene. J Immunol (2011) 0.92
Stromal cell contribution to human follicular lymphoma pathogenesis. Front Immunol (2012) 0.91
Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther (2006) 0.91
The role of macrophages in tumor development. Cell Oncol (2005) 0.91
Surgery-induced reactive oxygen species enhance colon carcinoma cell binding by disrupting the liver endothelial cell lining. Gut (2011) 0.90
Germ-line transcription occurs on both the functional and the non-functional alleles of immunoglobulin constant heavy chain genes. Eur J Immunol (2003) 0.89
The leishmania ARL-1 and Golgi traffic. PLoS One (2008) 0.89
Innate immune response of alveolar macrophage to house dust mite allergen is mediated through TLR2/-4 co-activation. PLoS One (2013) 0.89
Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood (2006) 0.88
Omental milky spots in peritoneal pathophysiology (spots before your eyes). Perit Dial Int (2005) 0.88
Transcription-dependent somatic hypermutation occurs at similar levels on functional and nonfunctional rearranged IgH alleles. J Immunol (2004) 0.88
Platelet activation after aortic prosthetic valve surgery. Interact Cardiovasc Thorac Surg (2005) 0.88
HLA-G and lymphoproliferative disorders. Semin Cancer Biol (2003) 0.87
Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol (2007) 0.87
Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology (2008) 0.87
Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol (2006) 0.87
The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19). BMC Biotechnol (2011) 0.86
Cross talk between immunoglobulin heavy-chain transcription and RNA surveillance during B cell development. Mol Cell Biol (2011) 0.86
Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica (2005) 0.85
Expression map of the human exome in CD34+ cells and blood cells: increased alternative splicing in cell motility and immune response genes. PLoS One (2010) 0.85